INTRON A MONOTHERAPY VS INTRON A+ RIBAVIRIN FOR TREATMENT OF CHRONIC HEPATITIS C

这项研究的主要目的是比较联合疗法(Intron A+利巴韦林)和单独使用Itron A治疗慢性丙型肝炎患者的总体活性/有效性和安全性。丙型肝炎几乎占所有输血相关性肝炎的病例，约占所有成人散发性急性肝炎病例的80%。尽管输血后感染丙型肝炎病毒(丙型肝炎病毒)的风险已降至1%以下，尽管这种感染的频率随着静脉注射药物相关病例的减少而开始下降，但新病例仍在继续被发现。在20年前尝试过静脉注射药物并在常规筛查中引起临床注意的人中，慢性感染的储备库仍然较大。在免疫能力正常的成年人中，估计有1%的急性乙肝病例进展为慢性，相比之下，50%-70%的急性丙型肝炎患者发展为慢性肝炎；即使在那些生化恢复的患者中，慢性感染的可能性也很高。因此，慢性肝炎和慢性感染的合并频率接近90%。S对于其他形式的慢性肝炎也是如此，这种疾病如果经常没有症状，但也可以发生潜伏的进展。在仅存在轻微的临床和生化异常的情况下，多达20%的慢性输血相关性丙型肝炎患者在输血后10年内进展为肝硬变。在那些患有肝硬变的人中，几十年后患上肝细胞癌是有风险的。

The primary objectives of this study are to compare the overall activity/ effectiveness and safety profile of combination therapy (Intron A + ribavirin) with Itron A alone for the treatment of chronic hepatitis C in patients who have not previously been treated with interferon. Hepatitis C accounts for almost all cases of transfusion-associated hepatitis and for approximately 80% of all cases of sporadic acute hepatitis among adults. ALthought the risk of acquiring infection with hepatitis C virus (HCV) after transfution has fallen to under 1% and although the frequency of this infection has begun to decline with a reduction in intravenous drug asociated cases, new cases continue to be discovered. A larger reservoir of chronic infection persists among those who experimented with intravenous drugs two decades ago and come to clinical attention during routine screening. In contrast to the estimated <1% of acoute hepatitis B cases among immunocompetent adults progressing to chronicity, chronic hepatitis develops in 50% - 70% of patients with acute hepatitis C; even among those who recover biochemically, the likelihood for chronic infection is high. Therefore, the combined frequency of both chronic hepatitis and chronic infection approaches 90%. s is true for other forms of chronic hepatitis, this disease if often asymptomatic; yet, insidious progression can occur. In the presence of only minimal clincial and biochemical abnormalities, as many as 20% of patients with chronic transfusion-associated hepatitis C have been observed to progress to cirrhosis within 10 years of transfusion. Among those with cirrhosis, there is a risk after several decades of hepatocellular carcinoma.